Quarry LP Acquires Shares of 74,000 Catalent, Inc. (NYSE:CTLT)

Quarry LP acquired a new stake in shares of Catalent, Inc. (NYSE:CTLT) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 74,000 shares of the company’s stock, valued at approximately $4,482,000. Catalent accounts for 1.1% of Quarry LP’s investment portfolio, making the stock its 8th largest holding.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brooklyn Investment Group purchased a new stake in shares of Catalent in the third quarter worth approximately $31,000. Sentry Investment Management LLC purchased a new stake in shares of Catalent in the third quarter worth approximately $53,000. Longfellow Investment Management Co. LLC raised its holdings in shares of Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares during the period. GAMMA Investing LLC raised its holdings in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after buying an additional 212 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. increased its holdings in Catalent by 57.5% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after purchasing an additional 431 shares during the period.

Catalent Stock Up 0.2 %

Shares of NYSE CTLT opened at $61.80 on Thursday. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $11.22 billion, a PE ratio of -27.35, a price-to-earnings-growth ratio of 2.44 and a beta of 1.15. The stock’s fifty day simple moving average is $60.00 and its two-hundred day simple moving average is $58.62. Catalent, Inc. has a 12-month low of $36.74 and a 12-month high of $62.08.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm’s revenue was up 4.2% compared to the same quarter last year. During the same period last year, the business posted ($0.10) EPS. As a group, analysts expect that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on CTLT shares. Robert W. Baird restated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. StockNews.com upgraded Catalent from a “sell” rating to a “hold” rating in a report on Monday. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Eight equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $63.40.

Insider Buying and Selling at Catalent

In other news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by corporate insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.